levicitam tablets film-coated
pharma start llc - levetiracetam - tablets film-coated - 500mg (30/3x10/) in blister, (60/6x10/) in blister
amoxil tablets
kievmedpreparat pjsc - amoxicillin (amoxicillin trihydrate) - tablets - 500mg
amoxil tablets
kievmedpreparat pjsc - amoxicillin (amoxicillin trihydrate) - tablets - 250mg
cartia
padagis israel agencies ltd, israel - acetylsalicylic acid - tablets enteric coated - acetylsalicylic acid 100 mg - acetylsalicylic acid - acetylsalicylic acid - the primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
pitrex
teva israel ltd - tolnaftate - cream - tolnaftate 1 % - other antifungals for topical use - topical treatment of superficial dermatomycoses.
streptomycin sulfate powder for solution for i/m injection
"sintez" ojsc - streptomycin (streptomycin sulfate) - powder for solution for i/m injection - 1000mg
vyvanse 50 mg
medison pharma ltd - lisdexamfetamine dimesylate - capsules - lisdexamfetamine dimesylate 50 mg - lisdexamfetamine - vyvanse is a central nervous system (cns) stimulant indicated for the treatment of attention deficit hyperactivity disorder (adhd) in patients ages 6 years and above.vyvanse is indicated for the treatment of moderate to severe binge eating disorder (bed) for patient over 18 years.limitation of use:vyvanse is not indicated or recommended for weight loss. use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. the safety and effectiveness of vyvanse for the treatment of obesity have not been established
purevax rcp felv
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals for felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease.onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.
azitrox powder for oral suspension
pharmstandard-leksredstva jsc - azithromycin (azithromycin dihydrate) - powder for oral suspension - 200mg/5ml
adenuric 120mg tablets film-coated
menarini-von heyden gmbh - febuxostat - tablets film-coated - 120mg